When tyrosine kinase inhibitor sunitinib can be discontinued in metastatic renal cell carcinoma to pancreas: a case report
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1752-1947
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
When tyrosine kinase inhibitor sunitinib can be discontinued in metastatic renal cell carcinoma to pancreas: a case report ; volume:12 ; number:1 ; day:20 ; month:3 ; year:2018 ; pages:1-5 ; date:12.2018
Journal of medical case reports ; 12, Heft 1 (20.3.2018), 1-5, 12.2018
- Urheber
-
Sbitti, Yassir
- Beteiligte Personen und Organisationen
-
Debbagh, Adil
Slimani, Khaoula
Mahi, Mohamed
Errihani, Hassan
Ichou, Mohamed
SpringerLink (Online service)
- DOI
-
10.1186/s13256-018-1597-z
- URN
-
urn:nbn:de:1111-2018052021881
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:56 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Sbitti, Yassir
- Debbagh, Adil
- Slimani, Khaoula
- Mahi, Mohamed
- Errihani, Hassan
- Ichou, Mohamed
- SpringerLink (Online service)
Ähnliche Objekte (12)
Personalized prescription of tyrosine kinase inhibitors in unresectable metastatic cholangiocarcinoma
Preclinical evaluation of sunitinib, a multi-tyrosine kinase inhibitor, as a radiosensitizer for human prostate cancer
Therapeutic efficacy of Sunitinib and other broad spectrum receptor tyrosine kinase inhibitors (RTKI) in bleomycin-induced pulmonary fibrosis
Differential Toxicities of Tyrosine Kinase Inhibitors in the Management of Metastatic Lung Cancer
Co-administration of tyrosine kinase inhibitors with rottlerin in metastatic prostate cancer cells
The multitargeted receptor tyrosine kinase inhibitor sunitinib induces resistance of HER2 positive breast cancer cells to trastuzumab-mediated ADCC
Editorial: Targeting bruton tyrosine kinase
Metastatic collecting duct carcinoma of the kidney treated with sunitinib
Surgery for metastatic tumors of the pancreas
Protein tyrosine kinase 2b inhibition reverts niche-associated resistance to tyrosine kinase inhibitors in AML
Newer Tyrosine Kinase Inhibitors for CML
Neurogenin 3 is regulated by neurotrophic tyrosine kinase receptor type 2 (TRKB) signaling in the adult human exocrine pancreas
Personalized prescription of tyrosine kinase inhibitors in unresectable metastatic cholangiocarcinoma
Preclinical evaluation of sunitinib, a multi-tyrosine kinase inhibitor, as a radiosensitizer for human prostate cancer
Therapeutic efficacy of Sunitinib and other broad spectrum receptor tyrosine kinase inhibitors (RTKI) in bleomycin-induced pulmonary fibrosis
Differential Toxicities of Tyrosine Kinase Inhibitors in the Management of Metastatic Lung Cancer
Co-administration of tyrosine kinase inhibitors with rottlerin in metastatic prostate cancer cells
The multitargeted receptor tyrosine kinase inhibitor sunitinib induces resistance of HER2 positive breast cancer cells to trastuzumab-mediated ADCC
Editorial: Targeting bruton tyrosine kinase
Metastatic collecting duct carcinoma of the kidney treated with sunitinib
Surgery for metastatic tumors of the pancreas
Protein tyrosine kinase 2b inhibition reverts niche-associated resistance to tyrosine kinase inhibitors in AML
Newer Tyrosine Kinase Inhibitors for CML
Neurogenin 3 is regulated by neurotrophic tyrosine kinase receptor type 2 (TRKB) signaling in the adult human exocrine pancreas
Personalized prescription of tyrosine kinase inhibitors in unresectable metastatic cholangiocarcinoma
Preclinical evaluation of sunitinib, a multi-tyrosine kinase inhibitor, as a radiosensitizer for human prostate cancer
Therapeutic efficacy of Sunitinib and other broad spectrum receptor tyrosine kinase inhibitors (RTKI) in bleomycin-induced pulmonary fibrosis
Differential Toxicities of Tyrosine Kinase Inhibitors in the Management of Metastatic Lung Cancer
Co-administration of tyrosine kinase inhibitors with rottlerin in metastatic prostate cancer cells
The multitargeted receptor tyrosine kinase inhibitor sunitinib induces resistance of HER2 positive breast cancer cells to trastuzumab-mediated ADCC
Editorial: Targeting bruton tyrosine kinase
Metastatic collecting duct carcinoma of the kidney treated with sunitinib
Surgery for metastatic tumors of the pancreas
Protein tyrosine kinase 2b inhibition reverts niche-associated resistance to tyrosine kinase inhibitors in AML
Newer Tyrosine Kinase Inhibitors for CML